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corneal confocal microscopy 
detects small nerve fibre damage 
in patients with painful diabetic 
neuropathy
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Neuropathic pain is believed to arise from damage to nociceptive C fibres in diabetic neuropathy 
(DN). We have utilised corneal confocal microscopy (CCM) to quantify the severity of small nerve 
fibre damage in relation to the severity of neuropathic pain and quality of life (QoL) in patients 
with and without painful DN. 30 controls and patients with painful (n = 78) and painless (n = 62) DN 
underwent assessment of large and small nerve fibre function, CCM, neuropathic symptoms (small fibre 
neuropathy symptom inventory questionnaire, neuropathic pain scale) and QoL (SF-36, pre-R-ODS and 
hospital anxiety and depression scale). Patients with painful compared to painless DN, had comparable 
neurophysiology and vibration perception, but lower corneal nerve fibre density (20.1 ± 0.87 vs. 
24.13 ± 0.91, P = 0.005), branch density (44.4 ± 3.31 vs. 57.74 ± 3.98, P = 0.03), length (19.61 ± 0.81 
vs. 22.77 ± 0.83, P = 0.01), inferior whorl length (18.03 ± 1.46 vs. 25.1 ± 1.95, P = 0.005) and cold 
sensation threshold (21.35 ± 0.99 vs. 26.08 ± 0.5, P < 0.0001) and higher warm sensation threshold 
(43.7 ± 0.49 vs. 41.37 ± 0.51, P = 0.004) indicative of small fibre damage. There was a significant 
association between all CCM parameters and the severity of painful neuropathic symptoms, depression 
score and QoL. CCM identifies small nerve fibre loss, which correlates with the severity of neuropathic 
symptoms and reduced QoL in patients with painful diabetic neuropathy.
Pain is one of the most disturbing symptoms that accompany diabetic peripheral neuropathy and can critically 
affect the patient’s quality of life in about one-third of patients with diabetic neuropathy1,2. The true prevalence 
of painful diabetic neuropathy (DN) may be even higher, as most patients either do not report their symptoms 
or attribute them to diabetes3 and there is disagreement between the patient’s and physician’s perception of pain4. 
Neuropathic pain usually manifests as “tingling”, “pins and needles”, deep and dull aching, burning or electrical 
sensation in the feet and lower limbs, with a reduced ability to perform daily activities, nocturnal exacerbation 
with disturbed sleep resulting in lower mood, anxiety, depression and reduced quality of life1.
The underlying mechanisms of painful DN are complex and include distal small fibre degeneration with 
regeneration5, autonomic dysfunction6, impaired skin microcirculation7 and epineurial blood flow8, altered 
sodium9 and calcium channel expression10, central sensitization11 and alterations in the spinal cord and brain12,13.
The diagnosis of painful DN is challenging and subjective, based on establishing neurologic deficits and iden-
tifying the type and severity of pain through validated questionnaires14 including neuropathic pain scale (NPS)15, 
small fibre neuropathy symptom inventory questionnaire (SFN-SIQ)16 and quality of life (QoL) through the hos-
pital anxiety and depression scale (HADS)17 and the 36-item short form health survey (SF-36)18. Although, pain 
questionnaires are easy to administer, they have limited sensitivity and low reliability19. Objective tests such as 
nerve conduction studies, quantitative sensory testing (QST), skin punch biopsy and CCM can help to define 
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underlying nerve damage. Two large neuropathy phenotyping studies have shown that nerve conduction studies 
do not differentiate painful from painless neuropathy20, although thermal thresholds were associated with the 
severity of painful diabetic neuropathy21. With regard to structural damage to small fibres, reduced intraepider-
mal nerve fibre length22 and increased regeneration and axonal swellings have been found in patients with painful 
DN23. Corneal confocal microscopy (CCM) is a rapid non-invasive surrogate marker for small nerve fibre damage 
in diabetic peripheral neuropathy24. In two small studies we and others showed greater corneal nerve fibre loss 
in the central cornea22,25 and inferior whorl26 in patients with painful compared to painless diabetic neuropathy.
This study aimed to establish if CCM can differentiate patients with painful compared to painless DN and 
whether the severity of corneal nerve damage was associated with the severity of neuropathic pain and quality 
of life.
Results
Demographic and clinical findings. Controls were age-matched with the patients with diabetes mellitus. 
Blood pressure (BP) was comparable between groups. The duration of diabetes was comparable between patients 
with painless and painful DN. 58% of patients with PDN were on pain medications. BMI (P < 0.005) and HbA1c 
(P < 0.0001) were significantly higher and total cholesterol (P < 0.0001), LDL (P < 0.05) and HDL (P < 0.04) were 
significantly lower in patients with painful DN compared to healthy controls. Patients with painless DN had a 
significantly higher HbA1c (P < 0.0001) and lower total cholesterol (P < 0.0001) compared to healthy controls. 
Total cholesterol (P = 0.03) and triglycerides (P = 0.01) were significantly higher in painful compared to painless 
DN (Table 1).
Neuropathy severity, neurophysiology and QST. NDS (6.79 ± 0.26 vs 5.89 ± 0.29 vs 1.0 ± 0.3, 
P < 0.0001) was significantly higher in painful and painless DN compared to healthy controls and was also sig-
nificantly higher in painful compared to painless DN (P = 0.05). Sural nerve conduction velocity (40.57 ± 0.77 
vs 39.97 ± 0.81 vs 49.16 ± 0.9, P < 0.0001) and amplitude (5.95 ± 0.67 vs 5.77 ± 0.68 vs 16.08 ± 1.56, P < 0.0001) 
were significantly lower and VPT (24.08 ± 1.35 vs 21.93 ± 1.47 vs 8.17 ± 1.06, P < 0.0001) was significantly higher 
in patients with painful and painless DN compared to healthy controls, but did not differ between patients with 
painful and painless DN. WT (43.7 ± 0.49 vs 41.37 ± 0.51 vs 38.24 ± 0.73, P < 0.0001) was significantly higher in 
patients with painful and painless DN compared to healthy controls and differed between painful and painless 
DN (P = 0.004). CT (21.35 ± 0.99 vs 26.08 ± 0.5 vs 27.67 ± 0.36) was lower in painful DN compared to painless 
DN (P < 0.00001) and controls (P < 0.0001) (Table 1).
Controls (n = 30) Painless DN (n = 62) Painful DN (n = 78)
Age 61.2 ± 1.33 66.09 ± 1.1 64.09 ± 1.16
Gender (female/male) 16/14 18/44 30/48
Duration of diabetes 
(years) N/A 23.67 ± 2.5 19.86 ± 1.6
T1DM/T2DM N/A 24/38 17/61
BP Systolic/ Diastolic 
(mmHg) 133.7 ± 2.7/73.4 ± 1.8 130.4 ± 3.2/66.8 ± 1.5 132.72 ± 2.44/71.8 ± 2.3
BMI (kg/m2) 27.6 ± 1.02 30.2 ± 1.12 33.1 ± 1.07^
Total cholesterol 
(mmol/L) 5.1 ± 0.19 3.77 ± 0.1^ 4.18 ± 0.1^*
HDL (mmol/L) 1.61 ± 0.08 1.42 ± 0.07 1.34 ± 0.05^
LDL (mmol/L) 2.77 ± 0.13 2.04 ± 0.3 1.98 ± 0.09^
Triglycerides (mmol/L) 1.63 ± 0.14 1.36 ± 0.12 1.92 ± 0.14*
HbA1c (mmol/mol) 38.04 ± 0.69 56.86 ± 2.17^ 59.8 ± 1.73^
HbA1c (%) 5.63 ± 0.06 7.35 ± 0.19^ 7.62 ± 0.15^
Sural velocity (m/s) 49.16 ± 0.9 39.97 ± 0.81^ 40.57 ± 0.77^
Sural amplitude (μV) 16.08 ± 1.56 5.77 ± 0.68^ 5.95 ± 0.67^
Cold threshold (°C) 27.67 ± 0.36 26.08 ± 0.5 21.35 ± 0.99^*
Warm threshold (°C) 38.24 ± 0.73 41.37 ± 0.51^ 43.7 ± 0.49^*
VPT (V) 8.17 ± 1.06 21.93 ± 1.47^ 24.08 ± 1.35^
NDS (0-10) 1.0 ± 0.3 5.89 ± 0.29^ 6.79 ± 0.26^*
CNFD (no./mm2) 32.58 ± 1.26 24.13 ± 0.91^ 20.1 ± 0.87^*
CNBD (no./mm2) 90.98 ± 5.4 57.74 ± 3.98^ 44.4 ± 3.31^*
CNFL (mm/mm2) 26.63 ± 0.98 22.77 ± 0.83^ 19.61 ± 0.81^*
IWL (mm/mm2) 35.19 ± 2.29 25.14 ± 1.95^ 18.03 ± 1.46^*
Table 1. Clinical demographics, peripheral neuropathy assessment and CCM in patients with painless and 
painful diabetic neuropathy. All data are presented as mean ± SE. HDL – high-density lipoprotein cholesterol, 
LDL – low-density lipoprotein cholesterol, VPT – vibration perception threshold, NDS – neuropathy disability 
score, CNFD – corneal nerve fibre density, CNBD – corneal nerve fibre branch density, CNFL – corneal nerve 
fibre length, IWL – inferior whorl length. ^P < 0.05 compared to controls, *P < 0.05 compared to painless.
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Corneal confocal microscopy. All CCM parameters were significantly lower in painless and painful DN com-
pared to healthy controls: CNFD (24.13 ± 0.91, P < 0.0001 and 20.1 ± 0.87, P < 0.0001), CNBD (57.74 ± 3.98, P < 0.0001 
and 44.4 ± 3.31, P < 0.0001), CNFL (22.77 ± 0.83, P = 0.02 and 19.61 ± 0.81, P < 0.0001) and IWL (25.14 ± 1.95, 
P = 0.001 and 18.03 ± 1.46, P < 0.0001) (Table 1, Figs. 1 and 2). In addition, CNFD (P = 0.005), CNBD (P = 0.03), CNFL 
(P = 0.01) and IWL (P = 0.005) were lower in patients with painful compared to painless DN (Table 1).
Association between CCM and quality of life. There were weak but significant correlations between the 
VAS score and CNFD (r = −0.2, P = 0.02), CNBD (r = −0.2, P = 0.02) and IWL (r = −0.4, P = 0.02). Also, there 
were significant positive correlations between the average SF-36 score with CNFD (r = 0.2, P = 0.01), CNBD 
(r = 0.3, P = 0.002), CNFL (r = 0.3, P = 0.01) and IWL (r = 0.5, P = 0.002) and significant negative correlations 
between the severity of depression measured using the HADS questionnaire with CNFD (r = −0.2, P = 0.01), 
CNBD (r = −0.3, P = 0.003), CNFL (r = −0.3, P = 0.008) and IWL (r = −0.5, P = 0.003). Significant inverse cor-
relations were found between the severity of neuropathic symptoms assessed using the SFN-SIQ questionnaire 
with CNFD (r = −0.2, P = 0.01), CNBD (r = −0.3, P = 0.007), CNFL (r = −0.2, P = 0.01) and IWL (r = −0.5, 
P = 0.002). With the pre-R-ODS questionnaire, there were significant positive correlations between the dimen-
sions of carry, move, handle the object with CNFD (r = 0.2, P = 0.04) and IWL (r = 0.3, P = 0.03). Walking and 
movement correlated significantly with CNFD (r = 0.2, P = 0.01), CNBD (r = 0.2, P = 0.01), CNFL (r = 0.2, 
P = 0.03) and IWL (r = 0.4, P = 0.01) and between self-care with CNFD (r = 0.2, P = 0.04) and between eating 
and CNFD (r = 0.3, P = 0.005), CNBD (r = 0.2, P = 0.01) and CNFL (r = 0.3, P = 0.004). There was a correlation 
between household activities with CNBD (r = 0.2, P = 0.02) and CNFL (r = 0.2, P = 0.04) and between IWL and 
daily tasks (r = 0.3, P = 0.03) and the ability to change and hold body position (r = 0.3, P = 0.02).
Neuropathic pain and QOL. The most common descriptors of neuropathic pain among patients with 
painful DN assessed with the NPS questionnaire were: ~95% suffered from unpleasantness and intensity, ~89% 
reported deep pain, ~70% reported itchiness and ~65% cold pain. Almost every individual experienced more 
than one type of pain. Based on the SFN-SIQ questionnaire, the most common symptoms among patients with 
painful DN were dry mouth (~72%), dizziness (~67%), diaorrhea (~67%) and sensitive skin (~63%) (Fig. 3a). 
83% of patients with dry mouth symptoms and 80% of patients with dizziness were on pain medications.
Patients with painful DN had a significantly reduced QoL compared to painless DN based on the SF-36 score 
(47.19 ± 2.92 vs. 77.04 ± 2.66, P < 0.0001). The HADS depression (7.23 ± 0.53 vs. 3.78 ± 0.51, P < 0.0001) and 
anxiety score (7.89 ± 0.56 vs. 4.09 ± 0.45, P < 0.0001) was higher in patients with painful compared to painless 
DN (Table 2). Based on HADS, 20% (11/55) of patients with painful DN and approximately 5% (2/41) of patients 
with painless DN suffered from anxiety, while 5.5% (3/55) of patients with painful DN and 7% (3/41) of patients 
with painless DN suffered from depression, however, 40% (22/55) of patients with painful DN and 5% (2/41) 
of patients with painless DN suffered from both – depression and anxiety, respectively (Fig. 3b). Patients with 
painful DN on treatment for neuropathic pain had significantly worse depression (P = 0.002) and anxiety scores 
(P = 0.05), SFN-SIQ (P < 0.0001) and quality of life (SF-36) (P = 0.003) (Supplementary Table S1).
Figure 1. CCM images of the central cornea and inferior whorl in a healthy control (a,d), patient with painless 
DN (b,e) and patient with painful DN (c,f).
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QoL was assessed using the pre-R-ODS questionnaire (Table 2, Fig. 3c). Almost all aspects of QoL were sig-
nificantly worse in patients with painful compared to painless DN: change and hold body position (52.56 ± 3.38 
vs. 83.93 ± 3.33, P < 0.0001), walking and movement (45.65 ± 3.52 vs. 79.19 ± 4.21, P < 0.0001), movement by 
transport (66.02 ± 3.26 vs. 86.01 ± 3.27, P < 0.0001), carry, move, handle object (70.53 ± 3.08 vs. 89.07 ± 2.99, 
P < 0.0001), self-care (78.39 ± 2.92 vs. 93.29 ± 2.14, P < 0.0001), household (64.38 ± 4.21 vs. 92.36 ± 2.42, 
P < 0.0001), daily tasks (64.4 ± 3.69 vs. 90.79 ± 2.81, P < 0.0001), meeting people (67.87 ± 4.09 vs. 92.47 ± 3.22, 
P < 0.0001) work, study, hobbies (71.81 ± 3.43 vs. 93.49 ± 2.04, P < 0.0001).
Discussion
Painful diabetic neuropathy has a major impact on the patient’s quality of life as a result of associated anxiety and 
depression27. The exact cause of neuropathic pain remains elusive28, especially as pain can be experienced when 
there is little or no existing damage to nerves and a patient with severe neuropathy may not have any complaints29. 
Previous studies have reported that damage to Aδ and C fibres is associated with neuropathic pain30,31. CCM can 
quantify small fibre pathology and stratify the severity of DN32. In the present study, we demonstrate greater 
small fibre dysfunction (warm and cold thresholds) and damage to corneal nerve fibres but no difference in large 
fibre measures such as VPT and nerve conduction studies in patients with painful compared to painless DN. This 
agrees with our recent study showing reduced corneal nerve parameters in patients with painful compared to 
painless DN and an association with the severity of pain26.
Quattrini et al.7 previously reported a greater reduction in corneal nerve fibre length and intra-epidermal 
nerve fibre length in patients with painful compared to painless DN22. Wang et al.25 reported significant alter-
ations in corneal nerve morphology and a direct correlation with the severity of pain25, whereas Cheng et al.23 
reported axonal swelling in patients with painful compared to painless DN23.
This study also demonstrates a significant reduction in cold sensation threshold and an increase in warm 
sensation threshold in patients with painful compared to painless DN, consistent with Raputova et al.21 who 
reported significantly worse cold and warm detection thresholds in patients with mild and moderate to severe 
neuropathic pain compared to patients without neuropathic pain21. Themistocleous et al.20 reported a significant 
abnormality in QST parameters in patients with neuropathic pain but found no difference in nerve conduction 
studies, intraepidermal nerve fibre density and cold pain threshold20. The current study strengthens the evidence 
of greater small fibre loss and dysfunction in patients with painful compared to painless neuropathy.
Figure 2. Dot plots of corneal nerve fiber parameters (mean ± SE): (a) corneal nerve fiber density (CNFD), (b) 
corneal nerve branch density (CNBD), (c) corneal nerve fiber length (CNFL), (d) inferior whorl length (IWL) 
in healthy controls and patients with painless and painful DN.
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Validated questionnaires are an important tool for the assessment of neuropathic pain and its effect on the 
patients quality of life33, allowing us to assess the effect on patients’ lives including their mood, daily activities and 
social life. We show a significant correlation between measures of corneal nerve damage, especially at the inferior 
whorl with the presence and severity of neuropathic pain, quality of life and severity of depression. However, 
this weak association should be interpreted cautiously and suggests that factors other than the extent of small 
fibre damage contribute to a worse QoL and severity of pain. Patients with painful DN also suffered from greater 
anxiety and depression compared to those with painless DN. Previously, Gore et al.34 also demonstrated higher 
scores of anxiety and depression in patients with more severe neuropathic pain34. Dizziness and dry mouth were 
the most common symptoms among patients with painful DN and could be attributed to concomitant use of 
medications to relieve neuropathic pain. The most common type of pain reported was deep pain, whilst the least 
Figure 3. Measures of QoL and pain. (a) Small fibre neuropathy symptom inventory questionnaire (SFN-SIQ) 
in patients with painful DN; (b) Hospital anxiety depression scale (HADS); (c) preliminary Rasch-built Overall 
Disability Scale (pre-R-ODS) in patients with painless and painful DN.
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common was itchy pain. Others using NPS have also reported sharp and deep pain to be common whilst itching 
and cold pain were infrequent1,35. Using the pre-R-ODS questionnaire we show a significant reduction in all 
dimensions of QoL except eating. The SF-36 average score indicated a significant reduction in QoL (e.g. physical 
functioning and health, wellbeing, emotional problems and general health) in patients with painful compared to 
painless DN.
To our knowledge this is the first study to evaluate the association between the severity of small fibre neurop-
athy using CCM and its relationship to the severity of painful symptoms, patient mood, daily activities, social life 
and overall QoL. Although the VAS is a validated scale for the assessment of the severity of pain, we acknowledge 
it is very subjective. Another limitation of the current study is the lack of validated neuropathy specific QoL tools 
such as NeuroQoL and Norfolk QoL-DN that more accurately quantify QoL in diabetic neuropathy.
In conclusion, we show that corneal confocal microscopy detects greater corneal nerve fibre loss in patients 
with painful diabetic neuropathy and this correlates with the severity of neuropathic pain, the patient’s mood and 
QoL. These data encourage further studies to assess the potential utility of CCM in relation to a change in the 
severity of neuropathic pain and quality of life in clinical intervention trials.
Methods
Study subjects. 140 patients with type 1 (n = 41) and type 2 diabetes (n = 99) and 30 age-matched healthy 
controls were studied. All participants underwent demographic and clinical examination, detailed assessment 
of peripheral neuropathy and ophthalmic examination. Participants with a history of malignancy, vitamin B12 
or folate deficiency, chronic renal and/or liver impairment, connective tissue or infectious disease, neuropathy 
of other cause than diabetes, current diabetic foot ulcer, corneal trauma, or systemic disease of the cornea and 
contact lens wear were excluded from the study. A signed consent form was obtained from each participant prior 
to taking part in the study. This study adhered to the tenets of the Declaration of Helsinki and was approved by 
Greater Manchester East Research Ethics Committee.
Demographic and clinical neuropathy assessment. BMI, blood pressure, lipid profile and glycated 
haemoglobin (HbA1c) were measured in each participant. Neurological deficits were measured using the sim-
plified Neuropathy disability score (NDS) (0-10) and patients were confirmed to have DN based on an NDS > 2. 
Further, based on the visual analogue scale (VAS), patients were divided into two groups of painful (VAS > 4) 
(n = 78) and painless DN (VAS ≤ 4) (n = 62)36.
Vibration perception threshold (VPT) was measured with a Neurothesiometer (Scientific Laboratory 
Supplies, Wilford, Nottingham, UK), and cold and warm perception thresholds were assessed with the neuro-
sensory analyzer (TSA-II NeuroSensory Analyzer, Medoc Ltd., Ramat-Yishai, Israel) on the dorsum of the left 
foot. In addition, sural sensory nerve amplitude and nerve conduction velocity were assessed by a consultant 
neurophysiologist using nerve conduction testing machine (Dantec “Keypoint” system, Dantec Dynamics Ltd., 
Bristol, North Somerset, UK).
Corneal confocal microscopy. All participants were examined using slit-lamp biomicroscopy to eliminate 
the presence of ocular surface infection, corneal ulceration and narrow angle glaucoma prior to CCM examina-
tion. Both eyes were examined with a laser-scanning CCM (Heidelberg Retinal Tomograph-III Rostock Cornea 
Module, Heidelberg Engineering GmbH, Heidelberg, Germany) using our previously established protocol37. 
Painless DN 
(n = 41)
Painful DN 
(n = 55)
HADS depression (0-21) 3.78 ± 0.51 7.23 ± 0.53*
HADS anxiety (0-21) 4.09 ± 0.45 7.89 ± 0.56*
SFN-SIQ (0-39) 5.13 ± 0.65 11.61 ± 0.91*
SF-36 (0-100) 77.04 ± 2.66 47.19 ± 2.92*
Pre-R-ODS (%)
• Change and hold body position (%) 83.93 ± 3.33 52.56 ± 3.38*
• Walking and movement (%) 79.19 ± 4.21 45.65 ± 3.52*
• Movement by transport (%) 86.01 ± 3.27 66.02 ± 3.26*
• Carry, move, handle the objects (%) 89.07 ± 2.99 70.53 ± 3.08*
• Self-care (%) 93.29 ± 2.14 78.39 ± 2.92*
• Eating (%) 98.57 ± 1.42 94.24 ± 1.93
• Household (%) 92.36 ± 2.42 64.38 ± 4.21*
• Daily tasks (%) 90.79 ± 2.81 64.4 ± 3.69*
• Meeting other people (%) 92.47 ± 3.22 67.87 ± 4.09*
• Work, study, hobbies (%) 93.49 ± 2.04 71.81 ± 3.43*
Table 2. Pain and Quality of Life in patients with painless and painful diabetic neuropathy. All the data are 
presented as mean ± SE. HADS – hospital anxiety and depression scale; SFN-SIQ – small fibre neuropathy 
symptom inventory questionnaire; SF-36 – 36-item short form health survey; Pre-R-ODS – preliminary Rasch-
built Overall Disability Scale. * P < 0.05 compared to painless.
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Central corneal nerves and the inferior whorl were imaged at the level of sub-basal nerve plexus. CCM provides 
two-dimensional images with a resolution of 10μm and a size of 384 × 384 pixels.
Six images from the central cornea and four images from the inferior whorl were selected following our 
established protocols38,39. All corneal parameters were quantified using manual purpose-designed software 
(CCMetrics, M.A. Dabbah, Imaging Science, The University of Manchester, Manchester, UK). Corneal nerve 
fibre density (CNFD) (no/mm2), branch density (CNBD) (no/mm2), fibre length (CNFL) (mm/mm2) and inferior 
whorl length (IWL) (mm/mm2) were quantified.
Pain and quality of life questionnaires. QoL was assessed using the validated Short Form 36 Health 
Survey (SF-36) score, preliminary Rasch-built Overall Disability Scale (pre-R-ODS), Hospital Anxiety Depression 
Scale (HADS) and small fibre neuropathy and symptom inventory questionnaire (SFN-SIQ). 96 patients com-
pleted all questionnaires.
SF-36 consists of 36 questions, divided into 8 dimensions and scored in a range 0-10018. Our analysis included 
a total score, which was an average value of all 8 dimensions.
A 146-item preliminary Rasch-built Overall Disability Scale (pre-R-ODS) was used to assess the different 
aspects of a patient’s QoL40. Each question was scored as 0 – not possible, 1 – possible with effort and 2 – easy to 
perform. However, in this study, we could not use Rasch model to interpret the pre-R-ODS questionnaire, as the 
number of participants who completed the questionnaire was less than the number of questions, hence not ful-
filling Rasch model requirements. Therefore, the pre-R-ODS questionnaire was divided into ten different dimen-
sions: change and hold body position, walking and movement by transport, carrying, moving, handling objects, 
self-care, eating, household, daily tasks, meeting other people and work, studies and hobbies. For each patient, the 
average score for each dimension was established and expressed as a percentage.
HADS was used to score depression and anxiety levels17. The questionnaire consisted of 14 items and was 
divided into 2 subscales: 7 questions for the assessment of depression and 7 questions for anxiety. Each question 
was scored in a range of 0-3; the higher number represented the more severe symptoms. The subscale score was 
summed up from each question (range 0-21) and an average depression and anxiety score was compiled.
Other neuropathy symptoms including dry mouth, dizziness, dry eyes, changes in sweating, were assessed 
using the validated small fibre neuropathy and symptom inventory questionnaire (SFN-SIQ). SFN-SIQ consisted 
of 13 items. For each item, the scale range was 0-3 where 0=never, 1=sometimes, 2=often and 3=always16. For 
each participant, the overall score for SFN-SIQ was obtained from the sum of all items.
Neuropathic pain scale (NPS), a scale that consists of 10 items, each on a scale ranging from 0-10 was used to 
assess the most common types of pain among patients with painful DN15.
Statistical analysis. IBM SPSS statistic software (Version 22.0 for Macintosh, IBM Corporation, New 
York, NY, USA) was used for the analysis. All values were calculated as mean ± standard error (SE). The signifi-
cance was considered as P < 0.05. To compare values between more than two groups, One-Way Anova (post-hoc 
Bonferroni for parametric parameters and LSD for non-parametric parameters) was used. Independent-samples 
T-test was used to compare mean values between two groups (Mann-Whitney U test for non-parametric). Pearson 
correlation coefficient (Spearman’s rank correlation coefficient for non-parametric) was measured to evaluate the 
association between variables. Graphs were made using GraphPad Prism software (Version 7.0c for Macintosh, 
GraphPad Software, La Jolla California, USA).
Data availability
The datasets generated and analysed during the study are available from the corresponding author on a reasonable 
request
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